Brain+ strategy update: Focus on the UK to reach proof-of-business and commercial scaling in 2024-2025
· The UK is assessed to be the most attractive and accessible market for Brain+’ digital dementia solutions, of which CST-Therapist Companion is the first · An endorsing partnership is in place with Quiddity Health, who has the strongest track record of bringing digital health products to scale in the UK · Commercial focus on the UK National Health System (NHS), which accounts for +80% of the country’s healthcare spend · Value inflection points are proof-of-business in 2024 and commercial scaling in 2025 · Important 2024 milestones for CST-Therapist Companion v2.0:
Q1: Start of